U.S. manufacturers of insulin and diabetes-related treatments asked a federal judge on Friday to dismiss two health centers’ antitrust class action over the companies’ denials of 340B pricing when covered entities use contract pharmacies.
In a Nov. 11 joint motion filed in federal district court in Rochester, N.Y., the companies (Sanofi, Lilly, Novo Nordisk, and AstraZeneca) say that the health centers (Mosaic Health of upstate New York and Central Virginia Health Services) lack standing to sue and offer no direct or circumstantial evidence of conspiracy to restrain trade.
U.S. manufacturers of insulin and diabetes-related treatments asked a federal judge on Friday to dismiss two health centers’ antitrust class action over the companies’ denials of 340B pricing when covered entities use contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
